SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01827436

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia

The purposes of this pilot research study are 1. To begin to test if two different types of physical therapy might have different results in children and adolescents who have had a prior stroke, and 2. To determine if either type of physical therapy causes changes in the brain signals that control leg muscles. All participants will receive physical therapy 3 times per week for 8 weeks. Half of the participants will receive typical physical therapy, such as walking practice, muscle strengthening, and balance training. Half of the participants will receive asymmetrical gait training physical therapy, which uses new technology to train each leg differently during walking practice. After enrolling, participants will be randomly assigned to the type of therapy. Measurements will be taken before, during, and after the 8 weeks of physical therapy. These include walking tests to measure symmetry, walking speed and daily step activity, and brain tests to measure the strength of the signals from the brain to the leg muscles. One blood test is also taken to identify if certain genetic factors affect how each child responds to the physical therapy.

NCT01827436 Stroke Hemiplegia
MeSH: Stroke Hemiplegia
HPO: Hemiplegia Spastic hemiparesis Stroke

2 Interventions

Name: Conventional physical therapy

Type: Behavioral

Conventional physical therapy

Name: Asymmetrical gait training

Type: Behavioral

Asymmetrical gait training


Primary Outcomes

Measure: Change in walking symmetry

Time: before and after 8 weeks of therapy

Secondary Outcomes

Measure: Change in walking speed

Time: before and after 8 weeks of therapy

Measure: Change in excitability of neural motor pathways

Time: before and after 8 weeks of therapy

Measure: Change in patient/parent satisfaction rating

Time: before and after 8 weeks of therapy

Measure: Change in community step activity

Time: before and after 8 weeks of therapy

Other Outcomes

Measure: Changes in walking ability and cortical excitability measures (detailed above)

Time: before and after a 4 week baseline phase; before and after a 4 week withdraw phase

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 V66M

We will also establish a genetic database to identify the presence or absence of two genetic variants [Apolipoprotein E (ApoE Є4) and val66met Brain-derived neurotropic factor (BDNF) polymorphisms] associated with decreased potential for neuroplasticity for planning future investigations. --- val66met ---



HPO Nodes


HPO:
Hemiplegia
Genes 27
COL4A1 COL4A2 CACNA1A KRAS PTPN22 GCDH FGFR1 CTLA4 GNAQ PRTN3 ATP1A2 ATP1A3 SUOX ADA2 CTC1 HLA-DPA1 DOCK8 HLA-DPB1 SLC1A3 POLA1 PRF1 SCN1A NOTCH3 SNORD118 TBC1D24 ARX PAH
Spastic hemiparesis
Genes 2
HMGCL PRNP
Stroke
Genes 117
MPL COL3A1 COL4A1 VHL TET2 TPP2 MYD88 COL5A1 FLNA TREX1 NPPA MYH11 HTRA1 ZMPSTE24 MYLK SH2B3 CLIP2 WFS1 CALR CYP11B1 MAT2A ACAD9 SMARCAL1 ACTA2 ACTB SLC19A2 GATA4 GATA6 ACTG1 BAZ1B DPM3 NR3C1 CPS1 ACVRL1 RFC2 APP GTF2IRD1 GDF2 ADA2 CBS MECP2 TTR ZAP70 ABCC6 NR2F2 NAGS SNAP29 STIM1 TGFB2 TGFB3 JAK2 TGFBR1 SLC2A10 TGFBR2 TGFBR3 CRELD1 MFAP5 MLXIPL ANGPTL6 LIMK1 OTC CCM2 FBN1 GTF2I THPO GLA PIGA TRNC LMNA COX1 COX2 COX3 GUCY1A1 PIK3C2A CYTB MTHFR LOX GYS1 JAG1 ND1 ND4 SCN5A ND5 AGXT ASS1 DYRK1B ND6 CST3 KCNQ1 TRNF TRNH ELN TRNK TRNL1 GNAQ PRKG1 RFT1 TRNQ PRKAG2 TRNS1 TRNS2 TRNV TRNW HBB ENG TNXB TBL2 MMUT PRNP TP53 NOTCH3 SMAD3 SMAD4 SON PCNT FOXE3 PMM2